Shiyao Group (01093.HK): The interim analysis of the KN026 pivotal Phase II/III clinical trial reached the primary endpoint of progression-free survival (PFS).

Zhixin Finance APP News, Sino Biopharmaceutical Limited (01093.HK) announced that its subsidiary Shanghai Jinmant BioTech Co., Ltd. has collaborated with Jiangsu Kang-Ning Jierui Biopharmaceutical Co., Ltd. to develop KN026 (recombinant humanized anti-HER2 bispecific antibody injection) for HER2-positive locally advanced, recurrent, or metastatic gastric cancer subjects who have failed at least one systemic treatment (must include trastuzumab in combination with chemotherapy). The pivotal Phase II/III clinical study (KC-WISE) has achieved the pre-specified primary endpoint of progression-free survival (PFS) as assessed by the Independent Data Monitoring Committee (IDMC), demonstrating statistical significance and clinical significance.